Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.59 |
| ▸ | CA9 | Q16790 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828558 | 0.81 | CA12 (0.55) | CA12CA9ALDH1A1KIF11CA1 | |
| SCHEMBL23564662 | 0.79 | CA12 (0.51) | CA12CA9KIF11CA1CA3 | |
| SCHEMBL20660673 | 0.76 | CA12 (0.44) | CA12CA9KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL27166021 | 0.75 | CA12 (0.60) | CA12CA9KIF11CA1CA3 | |
| SCHEMBL4178782 | 0.75 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| SCHEMBL28952803 | 0.74 | KDM4E (0.43) | KDM4ESMN1; SMN2MEN1ALDH1A1LMNA | |
| SCHEMBL19751539 | 0.74 | CA12 (0.46) | CA12CA9KDM4EALDH1A1LMNA | |
| SCHEMBL31118648 | 0.74 | F11 (0.46) | CA12CA9KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL29578522 | 0.74 | KDM4E (0.43) | KDM4ESMN1; SMN2MEN1ALDH1A1LMNA | |
| SCHEMBL27094596 | 0.74 | CA12 (0.54) | CA12CA9ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11498896-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-8604055-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-12-10 | — | — | US | disclosed |
| EP-1981342-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | Reddy US Therapeutics, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007075194-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075194-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-4780468-A | 8-trifluoromethyl quinolones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1988-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, DBI | CA12 4871/4885CA9 4820/4885KDM4E 1691/4885 |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | CA12 4541/4885CA9 4706/4885KDM4E 4433/4885 |
| US-11498896-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | CA12 4594/4885CA9 4863/4885KDM4E 4204/4885 |
| US-10633336-B2 | Dopamine D2 receptor ligands | DRD2, ARRB1, DRD3 | CA12 4685/4885CA9 4843/4885KDM4E 4325/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | CA12 4594/4885CA9 4863/4885KDM4E 4204/4885 |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | CA12 4594/4885CA9 4863/4885KDM4E 4204/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | CA12 4594/4885CA9 4863/4885KDM4E 4204/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | CA12 4871/4885CA9 4820/4885KDM4E 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.